<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HAA21EDF63C2F4253AC0079DD3AD005F8" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 6958 IH: Drug Price Transparency Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2018-09-27</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 6958</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20180927">September 27, 2018</action-date><action-desc><sponsor name-id="R000607">Mr. Francis Rooney of Florida</sponsor> (for himself and <cosponsor name-id="W000800">Mr. Welch</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To provide for a study and report on the feasibility of basing reimbursement rates for Medicare
			 part B drugs and covered part D drugs on the average prices for such drugs
			 in the member-states of the Organization for Economic Cooperation and
			 Development.</official-title></form>
	<legis-body id="HD03530E7F3384DE0BEACB3E1AE94E449" style="OLC">
 <section id="HE201555C93BE4009A4CFD21BCC37C8E5" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Drug Price Transparency Act</short-title></quote>.</text> </section><section id="H8F5562FFE1CC4E4DBC9B2512EE1E4CBA"><enum>2.</enum><header>Study and report on feasibility of basing reimbursement rates for Medicare part B drugs and covered part D drugs on average prices for such drugs in OECD member states</header><text display-inline="no-display-inline">From amounts otherwise made available to the Secretary of Health and Human Services, the Secretary shall use not to exceed $100,000 of such amounts to, not later than 90 days after the date of the enactment of this Act, conduct a study, and submit to Congress a report, on the feasibility of—</text>
 <paragraph id="H7C97801AC328472B9A83A18046FCF9A4"><enum>(1)</enum><text>basing reimbursement rates under part B of the Medicare program under title XVIII of the Social Security Act for prescription drugs for which coverage is provided under part B of the Medicare program on the average price of such drugs in the member-states of the Organization for Economic Cooperation and Development; and</text>
 </paragraph><paragraph id="H7AE97134ACD849ABB5E0AB26B489C998"><enum>(2)</enum><text>basing payment rates under prescription drug plans under part D of such title (and under MA–PD plans under part C of such title) for covered part D drugs (as defined in section 1860D–2(e) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-102">42 U.S.C. 1395w–102(e)</external-xref>)) on the average price of such drugs in such member-states.</text>
			</paragraph></section></legis-body></bill>


